GlassScriptPhysician profile
Davin Liimakka
NPI 1720718646
$530.94
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $92.99 · 2023: $228 · 2024: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $223.25 | 2023-2024 | Vistaseal, Xcm Biologic Tissue Matrix |
| Astrazeneca Pharmaceuticals LP | $57.46 | 2022-2024 | Andexxa |
| Integra Lifesciences Corporation | $53.00 | 2022-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Kci USA, INC. | $40.27 | 2022-2023 | V.A.C. Veraflo Cleanse Choice, Prevena |
| Depuy Synthes Sales INC. | $29.74 | 2023 | Xcm Biologic Tissue Matrix |
| Inari Medical, INC. | $26.08 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Lifenet Health | $20.19 | 2024 | Theragenesis Wound Matrix |
| Solventum Corporation | $17.80 | 2024 | Activ.A.C., Prevena |
| Ethicon US, LLC | $17.59 | 2023 | Echelon Flex |
| Bioventus LLC | $17.17 | 2022 | |
| Csl Behring | $15.46 | 2024 | Kcentra |
| Hydrofera LLC | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davin Liimakka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.